

PCM

PRECISION CANCER MEDICINE


A JOURNAL AIMING TO DELIVER A LASTING BLOW TO CANCER

PCM Annual Report
2020

Editorial Office pcm@amegroups.com





复旦大学附属肿瘤医院
Fudan University Shanghai Cancer Center



Outline of the Report


1. Basic Information
2. Distribution of Editorial Board Members
3. Articles Published (2020)
4. Articles Published (2018 - 2020)
5. Website Pageviews (2020)
6. Website Pageviews (2018 - 2020, Results by Year)
7. Website Users (2020)
8. Website Users (2018 - 2020)
9. Special Series (Published)
10. Special Series (Ongoing)



1. Basic Information

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216)

- Launched in April 2018
- An open access, peer-reviewed online journal
- The official journal of Fudan University Shanghai Cancer Center
- Dedicated to precise diagnosis and treatment of cancers and personalized care for patients
- To explore different kinds of cancers and different aspects of cancer research (oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing and etc)
- For more information, please visit: <http://pcm.amegroups.com/>




1. Basic Information

Editor-in-Chief



Xiaomao Guo, MD

Professor, Fudan University,
President, Fudan University Shanghai Cancer Center,
President, Shanghai Proton and Heavy Ion Center,
Shanghai, China




1. Basic Information

Executive Editor-in-Chief



Zhimin Shao, MD


Professor, Fudan University,
Director, Fudan University Cancer Institute and Breast
Cancer Institute,
Fudan University Shanghai Cancer Center,
Shanghai, China




“We would like to express our heartfelt appreciation to all the editorial board members, guest editors, authors, reviewers and readers for your precious support and contributions to the journal since its birth in April 2018. We would look forward to the joint efforts with colleagues in the field of cancer research in pursuit of precise diagnosis and treatment of cancers and personalized care for patients.”

Xiaomao Guo, MD
Editor-in-Chief, PCM

Zhimin Shao, MD
Executive Editor-in-Chief, PCM




2. Distribution of Editorial Board Members




Country	Number	%
USA	65	32%
Italy	35	17%
China	24	12%
France	14	7%
Spain	11	5%
Japan	8	4%
Germany	6	3%
Singapore	6	3%
Canada	6	3%
Austria	5	2%
Australia	4	2%
Switzerland	3	1%
Sweden	3	1%
Denmark	3	1%
The Netherlands	3	1%
Others	10	5%

Total: 206 members from 23 countries
 Honorary Editors-in-Chief: 3
 Editor-in-Chief: 1
 Excusive Editor-in-Chief: 1
 Associate Editors: 6
 Editorial Board Members: 195




3. Articles Published (2020)

The Proportion of different Article Types:
% of total: 100% (35 manuscripts)





Totally 35 manuscripts published in 2020.

Article Type	Number
Case Report	12
Review Article	9
Editorial/Commentary	9
Original Article	4
Letter to the Editor	1
Sum	35





3. Articles Published (2020)

Numbers of Corresponding Authors Classified by Countries (totally 35 corresponding authors from 11 countries)




4. Articles Published (2018 - 2020)

Numbers of Published Articles Classified by Year
(totally 95 articles)




4. Articles Published (2018 - 2020)


Distribution of Corresponding Authors:
% of total: 100% (95 authors from 19 countries)



Country	Number
USA	30
China	13
Italy	10
Spain	7
The Netherlands	6
France	6
Japan	4
Switzerland	3
Denmark	3
Israel	2
Germany	2
Brazil	2
Others	7
Sum	95




5. Website Pageviews (2020)




Total number of pageviews reached 45,202 from Jan -Dec 2020.

Data collected from Google Analytics on Jan 6, 2021.




6. Website Pageviews (2018 - 2020, Results by Year)




Total number of pageviews reached 80,990 from 2018 to 2020 .

Data collected from Google Analytics on Jan 6, 2021




7. Website Users (2020)

	14,080 % of Total: 100.00% (14,080)	14,080 % of Total: 100.00% (14,080)
1.  United States	5,262	37.24%
2.  China	1,592	11.27%
3.  India	743	5.26%
4.  Japan	718	5.08%
5.  United Kingdom	589	4.17%
6.  Italy	556	3.94%
7.  Canada	330	2.34%
8.  Netherlands	330	2.34%
9.  France	280	1.98%
10.  Germany	278	1.97%




The number of users reached 14,080 in 2020. Users from USA rank the first.

Data collected from Google Analytics on Jan 6, 2021.




8. Website Users (2018 - 2020)



Total number of users reached 22,146 from 2018 to 2020.

The number of users in 2020 is more than double the number in 2019.

Data collected from Google Analytics on Jan 6, 2021.



9. Special Series (Published)

1) Evidence and Controversies in the treatment of metastatic NSCLC

Guest Editor: Grace K. Dy, MD, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Table of Contents


Editorial

- On opposing ideas

Editorial Commentary

- ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)
- ADAURA: a definitive answer to the wrong question
- CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC
- Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
- Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
- The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
- Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”
- Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAFV600E mutation with PD-L1 90%—a debate in a niche population

GUEST EDITOR



9. Special Series (Published)

2) Series on Non-Small Cell Lung Cancer (NSCLC)

Guest Editors:

Alfredo Addeo, Oncology Department, University Hospital Geneva, Geneva, Switzerland

Giuseppe Banna, Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy

Table of Contents

Original Article

- Digging deep or spreading wide?—a comparison of polymerase chain reaction and sequencing approaches in the analysis of circulating tumor DNA


Review Article

- Role and room for biomarkers in non-small cell lung cancer
- The role of immunotherapy in mesothelioma
- Pathology in non-small cell lung cancer: evolving scenario
- Lung cancer screening: where do we stand?
- How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer
- Non-small cell lung cancer targetable mutations: present and future
- NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC)

GUEST EDITORS



ALFREDO ADDEO; GIUSEPPE BANNA



9. Special Series (Published)

3) [The series dedicated to the Congress on Clinical Controversies in Lung Cancer \(CCLC 2018\)](#)

Guest Editor: Nir Peled, Oncology Division, Ben-Gurion University, Beer-Sheva, Israel

Table of Contents

Editorial

- The current and future revolution in lung cancer screening and management


Review Article

- Prophylactic cranial irradiation (PCI) or magnetic resonance imaging (MRI) monitoring in limited small cell lung cancer: is it a question?
- Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options?
- ALK disease: best first or later, and do we care about variants?
- Low-dose lung cancer screening: nodule measurement and management
- Annotating the next generation sequencing report
- Non-small cell lung cancer PDL1 >50%—should we go single or combo?

GUEST EDITOR



NIR PELED



10. Special Series (Ongoing)

1) [Precision Oncology Tumor Board](#)

Guest Editor:


Balazs Halmos (Albert Einstein College of Medicine, USA)



2) [Management of Triple Negative Breast Cancer](#)

Guest Editor:

Jacques Raphael, MD (Western University, Canada)



10. Special Series (Ongoing)

3) [ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy](#)

Guest Editors:

Jesús Corral, MD (Clínica Universidad de Navarra, Spain);
Laura Mezquita, MD, PhD (Hospital Clinic, Barcelona, Spain);
Ernest Nadal, MD, PhD (University of Barcelona, Spain)

GUEST EDITORS



JESÚS CORRAL; LAURA MEZQUITA; ERNEST NADAL

4) [Lung Cancer In Women: From Epidemiology To Therapy](#)


Guest Editors:

Editta Baldini (San Luca Hospital, Italy);
Franca Melfi (University Hospital of Pisa, Italy)

GUEST EDITORS



EDITTA BALDINI; FRANCA MELFI



10. Special Series (Ongoing)

5) [Predictive and Prognostic Biomarkers in Tumors](#)

Guest Editors:


Mari Mino-Kenudson (Massachusetts General Hospital, USA);

Yin (Rex) P. Hung (Massachusetts General Hospital, USA)



6) [Genomic Instability, Clonal Evolution and Oncogenesis](#)

Guest Editor: Masood A. Shammam (Harvard/Dana Farber Cancer Institute, USA)



Our Publisher—

AME Publishing Company

www.amegroups.com

Established in 2009

Registered in Hong Kong

10 offices around the world

60+ peer-reviewed journals


13 indexed in SCIE

18 indexed in PubMed/PMC/MEDLINE

120+ Medical Books

(60+ in English & 60+ in Chinese)

120+ electronic editions





Thank you for your attention

